<DOC>
	<DOCNO>NCT00440349</DOCNO>
	<brief_summary>Idiopathic retroperitoneal fibrosis ( IRF ) rare disease characterise presence retroperitoneal periaortic fibro-inflammatory tissue may entrap ureter cause renal failure . The treatment IRF well established . Corticosteroids frequently use , anti-estrogen agent tamoxifen also report effective number report . However , randomise trial publish far . The aim present study compare efficacy prednisone tamoxifen treatment IRF .</brief_summary>
	<brief_title>Prednisone Versus Tamoxifen Idiopathic Retroperitoneal Fibrosis</brief_title>
	<detailed_description>Idiopathic retroperitoneal fibrosis ( IRF ) rare condition hallmarked presence retroperitoneal mass consist chronic inflammatory infiltrate abundant fibrous tissue . IRF usually present systemic inflammatory disease , constitutional symptom ( e.g . fatigue , weight loss ) high acute-phase reactant ; addition , IRF patient often complain abdominal lumbar pain , ureteral involvement present , may also show oliguria symptom related uremia . Ureteral obstructive disease usually manage placement ureteral indwelling stent , nephrostomy tube , severe case , surgical ureterolysis . These approach usually follow medical treatment . The medical treatment IRF largely empirical : corticosteroid routinely use , number report show tamoxifen may also effective . However , prospective control trial conduct patient condition . In study , compare efficacy prednisone tamoxifen IRF patient . Patients receive diagnosis IRF enrol , patient secondary form retroperitoneal fibrosis ( e.g . drug , infection , radiotherapy ) exclude . When present , ureteral obstruction manage ureteral stents/nephrostomy/ureterolysis . All patient receive oral prednisone ( 1 mg/kg/day ) one month , end randomize receive either tamoxifen ( 0.5 mg/kg/day fix dose 8 month ) prednisone ( 0.5 mg/kg/day first month , 0.25 mg/kg/day second third month , taper ensue 5 month ) . A CT/MRI study perform start treatment , four month randomization end treatment . All patient follow least 18 month end treatment . Disease remission define basis clinical symptom relate IRF ( e.g . pain , constitutional symptom ) , level acute-phase reactant ( erythrocyte sedimentation rate , C-reactive protein ) , ureteral obstruction ( assessed sonography CT/MRI scan ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Retroperitoneal Fibrosis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Diagnosis idiopathic perianeurismal retroperitoneal fibrosis Previously treat patient ; retroperitoneal fibrosis secondary drug ( e.g . methysergide , methyldopa , pergolide , ergot alkaloid ) , infection ( e.g . tuberculosis ) , cancer ( e.g . lymphoma , sarcoma ) , radiotherapy , trauma , major surgery , systemic connective tissue vasculitis disease ( e.g . SLE , panarteritis nodosa ) ; pregnancy ; active infection tumour ; know hypersensitivity prednisone tamoxifen ; uncontrolled diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Retroperitoneal fibrosis</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Obstructive uropathy</keyword>
	<keyword>Periaortic fibrosis</keyword>
	<keyword>Chronic periaortitis</keyword>
</DOC>